Close
Blog & Resources Camargo Blog March 28th, 2008

Approval Delays at FDA

One of the expected benefits of the new drug approval process under PDUFA is that drugs get approved within a certain timeframe, today about 10 months after submission. This often cited as a reason why generic companies are looking at 505(b)(2) – generic approval times are now stretching to 20+ months. Now comes the news that FDA is going to allow up to 10% of applications to miss the PDUFA deadlines and also miss the meeting deadlines [I usually provide a reference to the original, but the sources cite an internal FDA letter by John Jenkins].

Why the delay? FDA is getting more money, is authorized for 500+ people but HHS decided to take new employee processes away from FDA, resulting in decision delays. Reportedly, prospective employees give up waiting.

We continue to believe that a well-prepared meeting request will get scheduled before incomplete requests and that a very well done submission will get approved on time.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road,
Suite 203
Cincinnati, OH 45242
Durham Office
2505 Meridian Parkway,
Suite 150
Durham, NC 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights